Celgene Co. (CELG) Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC lowered its holdings in Celgene Co. (NASDAQ:CELG) by 12.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 109,873 shares of the biopharmaceutical company’s stock after selling 15,746 shares during the quarter. GW&K Investment Management LLC’s holdings in Celgene were worth $11,466,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Thompson Davis & CO. Inc. raised its position in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI raised its position in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the period. Robecosam AG purchased a new stake in Celgene in the third quarter valued at $114,000. Guidant Wealth Advisors purchased a new stake in Celgene in the third quarter valued at $119,000. Finally, Capital Bank & Trust Co raised its position in Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 517 shares during the period. Institutional investors own 77.84% of the company’s stock.

A number of equities research analysts have commented on CELG shares. BMO Capital Markets lifted their target price on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, November 17th. Cantor Fitzgerald set a $112.00 price objective on Celgene and gave the company a “hold” rating in a report on Wednesday, January 17th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a report on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley upgraded Celgene from an “underweight” rating to an “equal weight” rating in a report on Friday, October 27th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Celgene presently has a consensus rating of “Buy” and an average target price of $130.25.

In other Celgene news, insider Mark J. Alles acquired 3,260 shares of the stock in a transaction dated Thursday, February 8th. The stock was acquired at an average cost of $91.90 per share, with a total value of $299,594.00. Following the transaction, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.95% of the company’s stock.

Celgene Co. (NASDAQ:CELG) opened at $95.26 on Monday. The stock has a market capitalization of $71,652.25, a PE ratio of 13.89, a PEG ratio of 0.67 and a beta of 1.49. Celgene Co. has a 1 year low of $88.32 and a 1 year high of $147.17. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.61 EPS. equities research analysts predict that Celgene Co. will post 7.68 earnings per share for the current year.

Celgene declared that its board has initiated a stock buyback program on Wednesday, February 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.com-unik.info/2018/02/19/celgene-co-celg-shares-sold-by-gwk-investment-management-llc.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit